Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
Publication
, Conference
Medeiros, B; Hogge, D; Newell, L; Bixby, D; Solomon, S; Strickland, S; Lin, T; Erba, H; Powell, B; Podoltsev, N; Ryan, R; Chiarella, M ...
Published in: Clinical Lymphoma Myeloma and Leukemia
September 2017
Duke Scholars
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
September 2017
Volume
17
Start / End Page
S286 / S286
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Medeiros, B., Hogge, D., Newell, L., Bixby, D., Solomon, S., Strickland, S., … Lancet, J. (2017). Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. S286–S286). Elsevier BV. https://doi.org/10.1016/j.clml.2017.07.071
Medeiros, Bruno, Donna Hogge, Laura Newell, Dale Bixby, Scott Solomon, Stephen Strickland, Tara Lin, et al. “Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML).” In Clinical Lymphoma Myeloma and Leukemia, 17:S286–S286. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.07.071.
Medeiros B, Hogge D, Newell L, Bixby D, Solomon S, Strickland S, et al. Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S286–S286.
Medeiros, Bruno, et al. “Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML).” Clinical Lymphoma Myeloma and Leukemia, vol. 17, Elsevier BV, 2017, pp. S286–S286. Crossref, doi:10.1016/j.clml.2017.07.071.
Medeiros B, Hogge D, Newell L, Bixby D, Solomon S, Strickland S, Lin T, Erba H, Powell B, Podoltsev N, Ryan R, Chiarella M, Louie A, Lancet J. Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S286–S286.
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
September 2017
Volume
17
Start / End Page
S286 / S286
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences